Get the Stockscreener App
1.44
0.00%
0.00
Metavia Inc stock is traded at $1.44, with a volume of 68,496.
It is up +0.00% in the last 24 hours and up +15.20% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$1.44
Open:
$1.45
24h Volume:
68,496
Relative Volume:
0.33
Market Cap:
$7.44M
Revenue:
-
Net Income/Loss:
$-12.97M
P/E Ratio:
-0.2576
EPS:
-5.5898
Net Cash Flow:
$-15.70M
1W Performance:
-7.69%
1M Performance:
+15.20%
6M Performance:
-86.81%
1Y Performance:
-82.82%
1-Day Range:
$1.42
$1.47
1-Week Range:
$1.4101
$1.67
52-Week Range:
$1.17
$19.03
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.44 | 7.44M | 0 | -12.97M | -15.70M | -5.5898 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
MSN Money - MSN
MetaVia (MTVA) price target decreased by 71.04% to 19.72 - MSN
MTVA Stock Price, Quote & Chart | METAVIA INC (NASDAQ:MTVA) - ChartMill
MetaVia (NASDAQ: MTVA) seeks votes on directors, reverse split authority and equity plan at 2026 meeting - Stock Titan
[ARS] MetaVia Inc. SEC Filing - Stock Titan
MetaVia (MTVA) price target decreased by 22.49% to 123.93 - MSN
MetaVia (MTVA) Stock Asset Based Valuation (Smart Money Exits) 2026-04-20Crowd Entry Points - Cổng thông tin điện tử Tỉnh Sơn La
MetaVia (MTVA) seeks shareholder approval for reverse split, equity plan at June 8 meeting - Stock Titan
Investment Recap: What is the next catalyst for MetaVia IncInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
Performance Recap: Is MetaVia Inc a cyclical or defensive stockDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Are executives confident in MetaVia (MTVA) Stock | MTVA Q4 Earnings: Beats Estimates by $0.85Management Guidance - Newser
MetaVia begins higher-dose trial of obesity drug DA-1726 By Investing.com - Investing.com Australia
MetaVia (MTVA) Begins Patient Dosing in Phase 1 Clinical Trial - GuruFocus
MetaVia Doses First Patient in Higher-Dose Phase 1 Trial of Dual GLP-1/Glucagon Agonist DA-1726 for Obesity Treatment 1 - Minichart
MetaVia Advances DA-1726 Obesity Trial With First Patient - TipRanks
MetaVia, LifeMD, Nike - TradingView
MetaVia begins higher-dose trial of obesity drug DA-1726 - Investing.com
MetaVia doses first patient in higher‑dose Phase 1 DA-1726 study; data due Q4 2026 - TradingView — Track All Markets
MetaVia (Nasdaq: MTVA) doses first patient in higher-dose DA-1726 obesity trial - Stock Titan
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity - PR Newswire
Weekly Trades: Is MetaVia Inc in a consolidation phaseLayoff News & High Return Stock Watch Alerts - baoquankhu1.vn
MetaVia Inc. (MTVA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Update Recap: Is MetaVia Inc currently under institutional pressureMarket Trend Report & Community Consensus Picks - baoquankhu1.vn
MetaVia (NASDAQ: MTVA) registers resale of 936,846 shares - Stock Titan
[EFFECT] MetaVia Inc. SEC Filing - Stock Titan
MTVA Technical Analysis & Stock Price Forecast - Intellectia AI
Is MetaVia (MTVA) Stock Good for Active Traders | Price at $1.21, Down 0.82%Crowd Sentiment Stocks - Newser
Market Recap: Can MetaVia Inc continue delivering strong returns2026 Geopolitical Influence & Free Community Consensus Stock Picks - baoquankhu1.vn
Will MetaVia (MTVA) Stock Rise in 2026 | Price at $1.25, Down 0.79%Expert Breakout Alerts - Newser
Entry Recap: Can MetaVia Inc continue delivering strong returnsPortfolio Update Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
[POS AM] MetaVia Inc. SEC Filing - Stock Titan
MTVA Stock Analysis: MetaVia Inc. at 1.25 dollars with 4.17 percent session gain - Newser
1,896,385 Common Stock of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
29,514 Restricted Stock Units of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Market Trends: Can MetaVia Inc continue delivering strong returnsMarket Risk Analysis & Smart Swing Trading Alerts - baoquankhu1.vn
MTVA PE Ratio & Valuation, Is MTVA Overvalued - Intellectia AI
MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026… - scr.zacks.com
Portfolio Shifts: Can MetaVia Inc stock outperform in a bear market2026 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
MetaVia stock price target lowered to $20 by H.C. Wainwright - Investing.com UK
Bearish Setup: Is now the right time to enter MetaVia IncMarket Movers & Fast Gaining Stock Reports - baoquankhu1.vn
Buy Signal: Is now the right time to enter MetaVia IncQuarterly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Can MetaVia Inc stock outperform in a bear marketWeekly Gains Summary & Smart Swing Trading Alerts - baoquankhu1.vn
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution - Investing.com
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution By Investing.com - Investing.com India
Big Picture: Does MetaVia Inc outperform in volatile markets2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
MetaVia Inc 2025 Annual Report: Clinical Progress, Risk Factors, and Cardiometabolic Drug Pipeline Overview - Minichart
MetaVia Updates Investor Strategy for Obesity and MASH - TipRanks
MetaVia Reports Positive 2025 Financial Results and Advances DA-1726 & Vanoglipel Clinical Programs for Obesity and MASH - Minichart
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Metavia Inc Stock (MTVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | 10% Owner |
May 08 '25 |
Buy |
0.71 |
4,647,887 |
3,300,000 |
9,995,679 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):